FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004869810> ?p ?o ?g. }

• W2004869810 endingPage "226" @default.
• W2004869810 startingPage "219" @default.
• W2004869810 abstract "Background Hepatocellular cancer (HCC) is a leading cause of cancer-related death worldwide. Historically, doxorubicin (DOX) has been widely used against unresectable HCC with variable response rates. Materials and methods We hypothesized that DOX combined with mitogen-activated protein kinase kinase-extracellular signal-regulated kinase (MEK-ERK) targeted therapy may provide enhanced anti-cancer effects. Human HCC cell lines (HepG2, Hep3B) were treated with DOX and MEK enzyme inhibitors, U0126 or PD184161, alone or in combination. Growth, apoptosis, and ERK expression/MEK activity were respectively determined by proliferation assay, DNA fragmentation enzyme-linked immunoassay or fluorochrome inhibitor of caspases, and Western blot. Results DOX (0.01–1 μM) decreased cell proliferation in Hep3B cells (IC50 ∼ 0.12 μM) at 48 to 72 h; DOX was less effective in HepG2 cells (IC50 ∼ 0.25 μM). At early time points (30 min) after DOX treatment of Hep3B cells, MEK activity was unchanged at low doses and decreased at higher doses; after 24 h, phospho-ERK levels increased at higher doses. Contrarily, in HepG2 cells, DOX caused a sustained, dose-dependent increase in phospho-ERK levels at early and late time points. The MEK inhibitor U0126 decreased phospho-ERK in both HCC lines. In contrast to DOX, HepG2 cells were more sensitive than Hep3B cells to U0126. The combination of DOX with U0126 (or PD184161) resulted in greater inhibition of proliferation in HepG2 but not in Hep3B cells. This effect may be mediated in part by enhanced apoptosis. Conclusions The effect of DOX on early and late induction of MEK activity predicts its chemotherapeutic response in HCC. Furthermore, this effect may also determine the utility of MEK inhibitor combination treatment. Hepatocellular cancer (HCC) is a leading cause of cancer-related death worldwide. Historically, doxorubicin (DOX) has been widely used against unresectable HCC with variable response rates. We hypothesized that DOX combined with mitogen-activated protein kinase kinase-extracellular signal-regulated kinase (MEK-ERK) targeted therapy may provide enhanced anti-cancer effects. Human HCC cell lines (HepG2, Hep3B) were treated with DOX and MEK enzyme inhibitors, U0126 or PD184161, alone or in combination. Growth, apoptosis, and ERK expression/MEK activity were respectively determined by proliferation assay, DNA fragmentation enzyme-linked immunoassay or fluorochrome inhibitor of caspases, and Western blot. DOX (0.01–1 μM) decreased cell proliferation in Hep3B cells (IC50 ∼ 0.12 μM) at 48 to 72 h; DOX was less effective in HepG2 cells (IC50 ∼ 0.25 μM). At early time points (30 min) after DOX treatment of Hep3B cells, MEK activity was unchanged at low doses and decreased at higher doses; after 24 h, phospho-ERK levels increased at higher doses. Contrarily, in HepG2 cells, DOX caused a sustained, dose-dependent increase in phospho-ERK levels at early and late time points. The MEK inhibitor U0126 decreased phospho-ERK in both HCC lines. In contrast to DOX, HepG2 cells were more sensitive than Hep3B cells to U0126. The combination of DOX with U0126 (or PD184161) resulted in greater inhibition of proliferation in HepG2 but not in Hep3B cells. This effect may be mediated in part by enhanced apoptosis. The effect of DOX on early and late induction of MEK activity predicts its chemotherapeutic response in HCC. Furthermore, this effect may also determine the utility of MEK inhibitor combination treatment." @default.
• W2004869810 created "2016-06-24" @default.
• W2004869810 creator A5006832828 @default.
• W2004869810 creator A5015843387 @default.
• W2004869810 creator A5051059014 @default.
• W2004869810 creator A5054894772 @default.
• W2004869810 creator A5067719411 @default.
• W2004869810 creator A5085314218 @default.
• W2004869810 date "2008-12-01" @default.
• W2004869810 modified "2023-10-17" @default.
• W2004869810 title "The Effect of Doxorubicin on MEK-ERK Signaling Predicts Its Efficacy in HCC" @default.
• W2004869810 cites W1838206574 @default.
• W2004869810 cites W1963592300 @default.
• W2004869810 cites W1967715111 @default.
• W2004869810 cites W1974302097 @default.
• W2004869810 cites W1976700920 @default.
• W2004869810 cites W1981388207 @default.
• W2004869810 cites W2002159565 @default.
• W2004869810 cites W2009707997 @default.
• W2004869810 cites W2011826559 @default.
• W2004869810 cites W2016175249 @default.
• W2004869810 cites W2022634639 @default.
• W2004869810 cites W2050675499 @default.
• W2004869810 cites W2053763835 @default.
• W2004869810 cites W2060889467 @default.
• W2004869810 cites W2078353782 @default.
• W2004869810 cites W2101031676 @default.
• W2004869810 cites W2134596275 @default.
• W2004869810 cites W2137052325 @default.
• W2004869810 cites W2162468536 @default.
• W2004869810 cites W2346857231 @default.
• W2004869810 cites W4362203923 @default.
• W2004869810 doi "https://doi.org/10.1016/j.jss.2008.01.029" @default.
• W2004869810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18468633" @default.
• W2004869810 hasPublicationYear "2008" @default.
• W2004869810 type Work @default.
• W2004869810 sameAs 2004869810 @default.
• W2004869810 citedByCount "36" @default.
• W2004869810 countsByYear W20048698102012 @default.
• W2004869810 countsByYear W20048698102013 @default.
• W2004869810 countsByYear W20048698102014 @default.
• W2004869810 countsByYear W20048698102015 @default.
• W2004869810 countsByYear W20048698102016 @default.
• W2004869810 countsByYear W20048698102017 @default.
• W2004869810 countsByYear W20048698102018 @default.
• W2004869810 countsByYear W20048698102019 @default.
• W2004869810 countsByYear W20048698102020 @default.
• W2004869810 countsByYear W20048698102021 @default.
• W2004869810 countsByYear W20048698102023 @default.
• W2004869810 crossrefType "journal-article" @default.
• W2004869810 hasAuthorship W2004869810A5006832828 @default.
• W2004869810 hasAuthorship W2004869810A5015843387 @default.
• W2004869810 hasAuthorship W2004869810A5051059014 @default.
• W2004869810 hasAuthorship W2004869810A5054894772 @default.
• W2004869810 hasAuthorship W2004869810A5067719411 @default.
• W2004869810 hasAuthorship W2004869810A5085314218 @default.
• W2004869810 hasConcept C126322002 @default.
• W2004869810 hasConcept C184235292 @default.
• W2004869810 hasConcept C185592680 @default.
• W2004869810 hasConcept C190283241 @default.
• W2004869810 hasConcept C2776694085 @default.
• W2004869810 hasConcept C2781249067 @default.
• W2004869810 hasConcept C2781303535 @default.
• W2004869810 hasConcept C502942594 @default.
• W2004869810 hasConcept C55493867 @default.
• W2004869810 hasConcept C57074206 @default.
• W2004869810 hasConcept C62112901 @default.
• W2004869810 hasConcept C71924100 @default.
• W2004869810 hasConcept C98274493 @default.
• W2004869810 hasConceptScore W2004869810C126322002 @default.
• W2004869810 hasConceptScore W2004869810C184235292 @default.
• W2004869810 hasConceptScore W2004869810C185592680 @default.
• W2004869810 hasConceptScore W2004869810C190283241 @default.
• W2004869810 hasConceptScore W2004869810C2776694085 @default.
• W2004869810 hasConceptScore W2004869810C2781249067 @default.
• W2004869810 hasConceptScore W2004869810C2781303535 @default.
• W2004869810 hasConceptScore W2004869810C502942594 @default.
• W2004869810 hasConceptScore W2004869810C55493867 @default.
• W2004869810 hasConceptScore W2004869810C57074206 @default.
• W2004869810 hasConceptScore W2004869810C62112901 @default.
• W2004869810 hasConceptScore W2004869810C71924100 @default.
• W2004869810 hasConceptScore W2004869810C98274493 @default.
• W2004869810 hasIssue "2" @default.
• W2004869810 hasLocation W20048698101 @default.
• W2004869810 hasLocation W20048698102 @default.
• W2004869810 hasOpenAccess W2004869810 @default.
• W2004869810 hasPrimaryLocation W20048698101 @default.
• W2004869810 hasRelatedWork W1990511191 @default.
• W2004869810 hasRelatedWork W2062725558 @default.
• W2004869810 hasRelatedWork W2088338446 @default.
• W2004869810 hasRelatedWork W2109132296 @default.
• W2004869810 hasRelatedWork W2110980999 @default.
• W2004869810 hasRelatedWork W2487850446 @default.
• W2004869810 hasRelatedWork W2770034320 @default.
• W2004869810 hasRelatedWork W2896818550 @default.
• W2004869810 hasRelatedWork W3005630266 @default.
• W2004869810 hasRelatedWork W4226207639 @default.
• W2004869810 hasVolume "150" @default.

• next